RESEARCH · THE DMT ATLAS
The DMT Patent Landscape
You cannot patent DMT itself — the molecule is public domain. But 26 patents and applications try to own the periphery: formulations, salts, deuterated analogs, dose regimens, devices, and uses. This is the full record; for what it all means, start with Who Owns the Molecule?
Showing 26 of 26
| Assignee | Patent / application | Title | Molecule | Status | Filed |
|---|---|---|---|---|---|
| CaaMTech, Inc. | US12065405B2 ↗ | Prodrugs and conjugates of dimethyltryptamine | N,N-DMT | granted | 2024-08 |
| GH Research Ireland Ltd | EP3927337B1 ↗ | Mebufotenin (5-MeO-DMT) for use in treating major depressive disorder / treatment-resistant depression | 5-MeO-DMT | granted (effective 2024-02-14; expiry no earlier than 2040) | 2024-02 |
| William Shulman (individual) | US12396981B2 ↗ | Methods of using DMT | N,N-DMT | granted (Active) | 2024-03 |
| Biomind Labs Inc. | US 18/697,499 (application) ↗ | Encapsulated microparticles and nanoparticles of dimethyltryptamines | N,N-DMT | application (pending; withstood third-party observations) | 2024-04 |
| GH Research Ireland Ltd | US 18/675,614 (application) ↗ | 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) for Treating Depression | 5-MeO-DMT | pending — all pending claims rejected (novelty/obviousness) | 2024-05 |
| (PCT applicant — psychedelic developer) | WO2024/121253A1 ↗ | Novel N,N-dimethyltryptamine (DMT) derivatives and uses thereof | N,N-DMT | PCT application/published | 2024-06 |
| atai Life Sciences / Viridia Life Sciences (attributed) | US2023/0136824A1 ↗ | N,N-dimethyltryptamine (DMT) and DMT analog compositions, methods of making, and methods of use thereof | N,N-DMT | application/published | 2023-05 |
| (PCT applicant — psychedelic developer) | WO2023/076135A1 ↗ | N,N-dimethyltryptamine (DMT) crystalline products and methods of making the same | N,N-DMT | PCT application/published | 2023-05 |
| Cybin Inc (Small Pharma) | US11660289B2 ↗ | Deuterated or partially deuterated N,N-dimethyltryptamine compounds | N,N-DMT | granted | 2023-05 |
| Cybin Inc | US11746088B2 ↗ | Deuterated tryptamine compounds (deuterated 5-MeO-DMT analogs) | 5-MeO-DMT | granted (exclusivity to ~2041) | 2023-09 |
| Cybin Inc | US11771681B2 ↗ | Deuterated N,N-dimethyltryptamine analogs (composition of matter) | N,N-DMT | granted | 2023-10 |
| Small Pharma Ltd (Cybin Inc) | US11773062B2 ↗ | Deuterated compounds (medical use and synthesis of DMT analogs) | N,N-DMT | granted | 2023-10 |
| Viridia Life Sciences, Inc. (assigned to Atai Therapeutics, Inc.) | US2023/0321039A1 ↗ | N,N-dimethyltryptamine (DMT) and DMT analog compositions, methods of making, and methods of use thereof | N,N-DMT | application/published | 2023-10 |
| (psychedelic developer — attribution unresolved) | US2023/0406824A1 ↗ | Tryptamine derivatives and their therapeutic uses | tryptamine-general | application/published | 2023-12 |
| CaaMTech, Inc. (attributed) | US11292765B2 ↗ | Tryptamine prodrugs | tryptamine-general | granted | 2022-04 |
| atai Life Sciences AG | US11602521B2 ↗ | N,N-dimethyltryptamine compositions and methods | N,N-DMT | granted | 2022-04 |
| CaaMTech, Inc. (attributed) | US11332441B2 ↗ | Crystalline N-methyl tryptamine derivatives | tryptamine-general | granted | 2022-05 |
| CaaMTech, Inc. | US11643391B2 ↗ | Prodrugs and conjugates of dimethyltryptamine | N,N-DMT | granted | 2022-06 |
| Small Pharma Ltd (now Cybin Inc) | US11406619B2 ↗ | Novel injectable formulations of DMT-based compounds | N,N-DMT | granted | 2022-08 |
| Algernon Pharmaceuticals Inc. | Algernon AP-188 (DMT salt-form / method applications; number unresolved) | Novel DMT salt forms (pamoate, nicotinate) and methods for stroke and traumatic brain injury | N,N-DMT | application(s) filed 2021 — number not resolved via free sources | 2021-01 |
| Individual inventor (sole named inventor / registered patent attorney) | US11235110B1 ↗ | Delivery system for ayahuasca-like substances | N,N-DMT | granted | 2021-07 |
| Small Pharma Ltd (now Cybin Inc) | US11697638B2 ↗ | 5-methoxy-N,N-dimethyltryptamine crystalline forms | 5-MeO-DMT | granted | 2021-09 |
| Small Pharma Ltd (attributed) | US2021/0395201A1 ↗ | Synthesis of N,N-dimethyltryptamine-type compounds, methods, and uses | N,N-DMT | application/published | 2021-12 |
| Small Pharma Ltd / Cybin Inc (attributed) | US2021/0403426A1 ↗ | Deuterated N,N-dimethyltryptamine compounds | N,N-DMT | application/published | 2021-12 |
| Loren S. Miller (International Plant Medicine Corporation) | US PP5751 P ↗ | Banisteriopsis caapi, (cv) 'Da Vine' | ayahuasca | expired (patent term ended ~2003) | 1984-11 |
| Beckley Psytech Ltd (AtaiBeckley Inc.) | Beckley Psytech BPL-003 (US composition-of-matter; exact number unresolved) | Intranasal mebufotenin (5-MeO-DMT) benzoate formulation (BPL-003) | 5-MeO-DMT | granted composition-of-matter (US, UK, EP) — exact US number not resolved via free sources |
Sources: PatentsView (USPTO) and Google Patents public records. Bibliographic metadata only — claim types and status, never enabling chemistry. Verify each at the linked primary record.